title: Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation.
abstract: This study investigates the significance of the glucose-6-phosphate dehydrogenase (G6PD) catalyzed oxidative and the transketolase (TK) catalyzed nonoxidative pentose cycle (PC) reactions in the tumor proliferation process by characterizing tumor growth patterns and synthesis of the RNA ribose moiety in the presence of respective inhibitors of G6PD and TK. Mass spectra analysis of 13C-labeled carbons revealed that these PC reactions contribute to over 85% of de novo ribose synthesis in RNA from [1,2-(13)C]glucose in cultured Mia pancreatic adenocarcinoma cells, with the fraction synthesized through the TK pathway predominating (85%). Five days of treatment with the TK inhibitor oxythiamine (OT) and the G6PD inhibitor dehydroepiandrosterone-sulfate (0.5 microM each) exerted a 39 and a 23% maximum inhibitory effect on cell proliferation in culture, which was increased to 60% when the two drugs were administered in combination. In vivo testing of 400 mg/kg OT or dehydroepiandrosterone-sulfate in C57BL/6 mice hosting Ehrlich's ascitic tumor cells revealed a 90.4 and a 46% decrease in the final tumor mass after 3 days of treatment. RNA ribose fractional synthesis through the TK reaction using metabolites directly from glycolysis declined by 9.1 and 23.9% after OT or the combined treatment, respectively. Nonoxidative PC reactions play a central regulating role in the carbon-recruiting process toward de novo nucleic acid ribose synthesis and cell proliferation in vitro and in vivo. Therefore, enzymes or substrates regulating the nonoxidative synthesis of ribose could also be the sites to preferentially target tumor cell proliferation by new anticancer drugs.
authors.affiliation: The Ohio State University College of Medicine, Department of Surgery, Columbus 43210, USA. lboros@magnus.acs.ohio-state.edu
authors.forename: L G
authors.initials: LG
authors.lastname: Boros
authors.forename: J
authors.initials: J
authors.lastname: Puigjaner
authors.forename: M
authors.initials: M
authors.lastname: Cascante
authors.forename: W N
authors.initials: WN
authors.lastname: Lee
authors.forename: J L
authors.initials: JL
authors.lastname: Brandes
authors.forename: S
authors.initials: S
authors.lastname: Bassilian
authors.forename: F I
authors.initials: FI
authors.lastname: Yusuf
authors.forename: R D
authors.initials: RD
authors.lastname: Williams
authors.forename: P
authors.initials: P
authors.lastname: Muscarella
authors.forename: W S
authors.initials: WS
authors.lastname: Melvin
authors.forename: W J
authors.initials: WJ
authors.lastname: Schirmer
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000473:pathology; D002286:Carcinoma, Ehrlich Tumor / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D019314:Dehydroepiandrosterone Sulfate / Q000494:pharmacology*; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism*; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins / Q000378:metabolism*; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010119:Oxythiamine / Q000494:pharmacology*; D010190:Pancreatic Neoplasms / Q000473:pathology; D010427:Pentose Phosphate Pathway / Q000187:drug effects*; D012334:RNA, Neoplasm / Q000378:metabolism; D012266:Ribose / Q000096:biosynthesis*; D014174:Transketolase / Q000378:metabolism*; D014305:Triose-Phosphate Isomerase / Q000378:metabolism*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
chemical_list: D009363:Neoplasm Proteins; D012334:RNA, Neoplasm; D010119:Oxythiamine; D019314:Dehydroepiandrosterone Sulfate; D012266:Ribose; D005954:Glucosephosphate Dehydrogenase; D014174:Transketolase; D014305:Triose-Phosphate Isomerase